Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer.
Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer.
复制标题
DOI：
--
复制
发表时间：
2002-03
期刊：
影响因子：
11.2
通讯作者：
M. Yasuda;M. Takenoyama;Y. Obata;M. Sugaya;T. So;T. Hanagiri;K. Sugio;K. Yasumoto
中科院分区：
文献类型：
--
作者：
M. Yasuda;M. Takenoyama;Y. Obata;M. Sugaya;T. So;T. Hanagiri;K. Sugio;K. Yasumoto
使用新鲜分离的肿瘤浸润B淋巴细胞（TI B）进行的功能研究难以进行和解释。在这里，我们使用移植到SCID小鼠中的新鲜人肺癌组织记录了TI B的新功能;它们处于活化状态并在肿瘤微环境中产生肿瘤特异性抗体：（a）移植到SCID小鼠中的TI B产生人IgG;（B）来自TI B的IgG高度结合自体癌细胞的细胞内和膜结合抗原;和（c）与来自患者血清的IgG相比，来自TIB的IgG对正常淋巴细胞上表达的自身抗原的识别更少。在这项研究中提出的新的发现的基础上，我们修改了原来的血清学分析抗原的重组cDNA表达克隆设计的肺癌患者表达异常有利的临床演变和分析体液免疫对确定突变的p53抗原。本研究提供了第一个证明，来自TIB的抗体识别肿瘤抗原的抗原的血清学分析，重组cDNA表达克隆方法和循环抗p53抗体在血清中来自TIB在肿瘤微环境。我们使用TIB的方法可以识别体液癌症相关免疫系统中的关键抗原。
Functional studies using freshly isolated tumor-infiltrating B lymphocytes(TIB) are difficult to perform and interpret. Here we document a novel function of TIB using fresh human lung cancer tissues engrafted in SCID mice; they are at activated state and produce tumor-specific antibodies in tumor microenvironment: (a) TIB engrafted in SCID mice produced human IgG; (b) IgG derived from TIB highly bound intracellular and membrane-bound antigens of autologous cancer cells; and (c) less recognition of autoantigens expressed on normal lymphocytes by IgG derived from TIB compared with IgG from the serum of the patient. On the basis of the novel findings presented in this study, we modified the original serological analysis of antigens by recombinant cDNA expression cloning design in a patient with lung cancer who expressed unusually favorable clinical evolution and analyzed humoral immunity against identified mutated p53 antigen. This study provides the first demonstration that antibodies derived from TIB recognize tumor antigens by serological analysis of antigens by recombinant cDNA expression cloning methodology and circulating anti-p53 antibodies in sera derived from TIB in tumor microenvironment. Our approach using TIB may allow the identification of key antigens in the humoral cancer-related immune system.